Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Brentuximab Vedotin As Monotherapy for Unresectable Breast Implant‐associated Anaplastic Large Cell Lymphoma

Anthony Stack, Isaac Levy

Clinical case reports（2019）

Cited 9|Views0
No score
Abstract
BI-ALCL is a rare CD30+ T-cell malignancy, which is known to complicate textured breast implants. The CD30-targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI-ALCL; however, its efficacy for unresectable BI-ALCL has not been demonstrated. We present a case of unresectable BI-ALCL, which was successfully treated with brentuximab vedotin.
More
Translated text
Key words
ALCL,breast implant-associated anaplastic large cell lymphoma,breast lymphoma,brentuximab vedotin,lymphoma
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined